Panaxia Pharmaceuticals Industries Ltd.

About Panaxia Pharmaceuticals Industries Ltd.

For more than a decade, Panaxia has been focusing on medical cannabis innovation - from early-stage R&D to commercialization. Millions of doses of our products have been consumed by patients worldwide – in multiple formulations and for multiple indications. 
Being part of an experienced pharma group in Israel, that boasts more than four decades of success, is what drives us to meet pharmaceutical standards in everything we do. This includes a reproducible API, adherence to stringent GMP guidelines, and maintenance of dose accuracy in every product we sell. 

Panaxia Labs Israel, Ltd. is a publicly traded company at TASE (TASE: PNAX). It is a global pharma company, that develops, manufactures, and markets advanced medical cannabis products of pharmaceutical high quality. Panaxia, the pioneer and largest medical cannabis manufacturer in Israel, is the only company in Israel with an EU-GMP approved factory from the European Health Authority, which is required for the commercial production and export of medical cannabis and its products to Europe. Panaxia specializes in the development, production, and marketing of complex and advanced cannabis plant products, based on clinical information and a broad database of tens of thousands of patients .

Panaxia Israel is a subsidiary of the Panaxia Pharmaceutical Industries, established in 2010 by Dr. Dadi Segal (PhD), Dr. Eran Goldberg (PhD) and Assi Rotbart (LL. B), as the cannabis division of Segal Pharma Group, operating for over four decades, producing more than 600 different pharmaceutical products distributed in over 40 countries. The Panaxia Group has over 150 employees. 
We invite you to discuss partnership opportunities with us and to join our exciting journey.

Certifications
  • IL
  • 2019
    On CPhI since
  • 2
    Certificates
  • 100 - 249
    Employees
Manufacturer/Innovator
Contact info

Products from Panaxia Pharmaceuticals Industries Ltd.

  • NAXIVA-PANAXOL Basic kits; Pharmaceutical Intermediates for magistral preparation of cannabis

    Product NAXIVA-PANAXOL Basic kits; Pharmaceutical Intermediates for magistral preparation of cannabis

    Standardized extract in oily matrix (Middle Chain Triglycerides [MCT] oil)
    We make kits to prepare full spectrum medical cannabis oils at various concentrations to treat a broad range of diseases. These kits contain constant and accurate concentrations of active substances and are simple to use by pharmacists. They include everything necessary to prepare personalized medical cannabis oils, according to the physician’s prescription, ready to be delivered to patients.

     Total amount: 30 ml
    Available in 4 different concentrations
  • NAXIVA-PANAXOL Advanced kits of Pharmaceutical Intermediates for magistral preparation of cannabis

    Product NAXIVA-PANAXOL Advanced kits of Pharmaceutical Intermediates for magistral preparation of cannabis

    Standardized extract in oily matrix (Middle Chain Triglycerides [MCT] oil)
    We make kits to prepare full spectrum medical cannabis oils at various concentrations to treat a broad range of diseases. These kits contain constant and accurate concentrations of active substances and are simple to use by pharmacists. They include everything necessary to prepare personalized medical cannabis oils, according to the physician’s prescription, ready to be delivered to patients.

    Total amount: 32 ml
    Available in 2 different concentrations

  • NAXIVA - PANAXOL Purified Medical Cannabis Extract for Inhalation

    Product NAXIVA - PANAXOL Purified Medical Cannabis Extract for Inhalation

    Purified standardized cannabis extract for inhalation THC 8.7 mg in 10 μl(THC 85% w/w), 0.85 g filled in a 1 ml syringe.
    Route of administration: Cannabis purified extract is intended for inhalation using a vaporizer. The rate of blood absorption of cannabis products is largely determined by the route of administration. Following inhalation, peak plasma concentrations are reached within 3–10 minutes, which provides a rapid onset of the clinical effect. Using vaporization to administer cannabinoids avoids the respiratory hazards associated with exposure to toxic pyrolytic compounds formed by combustion during smoking. Vaporization technology provides a safer alternative by decreasing respiratory and oncological risks while maintaining the pharmacokinetic advantages comparable to smoking, such as the rapid absorption via the lungs directly into the circulatory system. The extract to be vaporized can be dosed precisely as required using the graduated syringe. Thus, the patient can inhale a single, precise dose each time. Purified standardized extract for inhalation provides more accurate and consistent dosage form, allowing safer medical cannabis administration superior to smoking.
  • NAXIVA-PANAXIR Medical Cannabis Sublingual Tablets

    Product NAXIVA-PANAXIR Medical Cannabis Sublingual Tablets

    NAXIVA-PANAXIR sublingual tablets have been developed in order to offer rapid disintegration under the tongue, allowing the active ingredients to be available to penetrate under the tongue through the mucous membrane, and to improve the palatability, and taste masking of the drug substances.
    The tablets are available in bottles of either 7 or 30 tablets. They are formulated with a whole extract of the inflorescence of medical cannabis.
    The tablets offer substantial advantage over oils:• pleasant taste• simple administration and accurate dosing• improved patient compliance.
    The tablets contain: • Active substances: cannabis extract, comprising Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
    .• Other ingredients: mannitol, glycine, microcrystalline cellulose, croscarmellose sodium, povidone, levomenthol, sucralose, magnesium stearate.

    NAXIVA-PANAXIR sublingual tablets can be divided in half along the cut line to allow precise dosing.
    Available in 2 different concentrations.
  • NAXIVA-PANAXOL-ONKO Pharmaceutical intermediates for magistral preparations of medical cannabis

    Product NAXIVA-PANAXOL-ONKO Pharmaceutical intermediates for magistral preparations of medical cannabis

    Standardized extract in oily matrix (Middle Chain Triglycerides [MCT] oil)
    We make kits to prepare full spectrum medical cannabis oils at various concentrations to treat a broad range of diseases. These kits contain constant and accurate concentrations of active substances and are simple to use by pharmacists. They include everything necessary to prepare personalized medical cannabis oils, according to the physician’s prescription, ready to be delivered to patients.

    Naxiva Panaxol Onko 
    is characterized by designated formulations and new extracts adapted for oncology patients in Israel. The products were developed based on extensive clinical data accumulated in Panaxia for over a decade and its comprehensive experience in treating cancer patients in Israel.

    Total amount: 30 ml

    Available in 3 different concentrations
  • NAXIVA-PANAXIR Medical cannabis oral oil

    Product NAXIVA-PANAXIR Medical cannabis oral oil

    NAXIVA-PANXIR oral oil are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency.

    Total amount: 10/30 ml
    Available in 2 different concentrations
  • AXIBAN Medical Cannabis Sublingual Drops

    Product AXIBAN Medical Cannabis Sublingual Drops

    AXIBAN sublingual drops are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency.

    Total weight: 10 gr.Available in 11 different concentrations.
  • PANAXIR Medical Cannabis Sublingual Drops

    Product PANAXIR Medical Cannabis Sublingual Drops

    PANAXIR sublingual drops are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency.

    Total amount: 30 ml
    PANAXIR is available in 4 different concentrations | Available with dropper or syringe
  • PANAXIR SENSE PURE Medical cannabis sublingual drops

    Product PANAXIR SENSE PURE Medical cannabis sublingual drops

    PANAXIR SENSE PURE sublingual drops are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency.

    Total amount: 10.4 ml
    Available in 3 different concentrations.
  • PANAXIR SENSE MINT Medical cannabis sublingual drops

    Product PANAXIR SENSE MINT Medical cannabis sublingual drops

    PANAXIR SENSE MINT sublingual drops are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency. 

    Total amount: 10.4 ml
    Available in 3 different concentrations.
  • PANAXIR SENSE FRUITY Medical cannabis sublingual drops

    Product PANAXIR SENSE FRUITY Medical cannabis sublingual drops

    PANAXIR SENSE FRUITY sublingual drops are a full spectrum extract medical cannabis products that contain consistent and accurate concentrations of active substances. These products are made by validated pharmaceutical manufacturing process in order to ensure product quality and API consistency.
    Total amount: 10.4 ml
    Available in 3 different concentrations.

Panaxia Pharmaceuticals Industries Ltd. Resources

  • News Panaxia and Neuraxpharm are the world's first companies to sell medical cannabis extracts for inhalation in Europe

    Tel Aviv, November 3, 2021- Panaxia Labs Israel Ltd. (“Panaxia Israel,” TA: PNAX), a global pharma company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality announced the first commercial export of its medical cannabis extracts for inhalation to Germany, where it will be marketed under the Naxiva-Panaxol brand, which Panaxia shares with its partner, Neuraxpharm, Europe's leading Pharma Company focused on the treatment of Central Nervous System (CNS) disorders.
  • Video Panaxia Corporate Video

    We invite you to watch a movie that takes you through the world of Panaxia.
    Panaxia Labs Israel is a global pharma company, that develops, manufactures, and markets advanced medical cannabis products of pharmaceutical high quality. Panaxia is transforming cannabis herbal substances into consistent, effective, high-quality products that can be used the same way as other medicines.